C14 ADME Studies

Product description

 If your drug is approaching the end of Phase II clinical development or you are planning for your regulatory submission, Quotient Sciences can help you meet your program goals. With many years’ experience as a leading provider of human ADME 14C radiolabeled studies, we have the scientific expertise and operational know-how to design and deliver human ADME programs in preparation for NDA, MAA and global regulatory filings.  For more information visit: https://www.quotientsciences.com/services/clinical-pharmacology/human-adme/
Read more

More products from Quotient Sciences

View all our products (13)

Products from other suppliers